https://www.selleckchem.com/pr....oducts/pembrolizumab
embrane oxygenation circuit-related thrombotic events as well as a significant decrease in volume of blood products administered. Patients receiving bivalirudin for systemic anticoagulation on venovenous extracorporeal membrane oxygenation experienced a decrease in the number of extracorporeal membrane oxygenation circuit-related thrombotic events as well as a significant decrease in volume of blood products administered. Following return of spontaneous circulation after cardiac arrest, hypoxic ischemic brain injury is the primary
Curtir
Comentario
Compartilhar
